Biotech RadarJobs updated

COMPANY

Bio-Path Holdings

biopathholdings.com ↗ · Mid-Atlantic

FDA-cleared device company Clinical Phase 2

Keywords: oncology cancer RNA therapeutics blood cancers solid tumors Myelodysplastic Syndrome Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Ovarian Epithelial Carcinoma Fallopian Tube Neoplasms Endometrial Cancer Peritoneal Cancer Mantle Cell Lymphoma Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Hodgkin Lymphoma Waldenstrom Macroglobulinemia DLBCL Ph1-Positive Chronic Myelogenous Leukemia Recurrent Adult Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Ph1 Positive CML BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) L-Bcl-2 antisense oligonucleotide BP1001 (varying dose) BP1001 (fixed dose) BP1001

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: BP1001-A in Patients With Advanced or Recurrent Solid Tumors source ↗
  2. Trial start Phase 1: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) source ↗
  3. Trial start Phase 1: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies source ↗
  4. Trial start Phase 1/Phase 2: Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS source ↗
  5. Trial start Phase 2: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML source ↗
  6. Trial start Phase 1: Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05190471A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)Phase 1RecruitingAug 16, 20222027-03 (estimated)
NCT02781883Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLPhase 2Recruiting2016-052027-12 (estimated)
NCT04196257BP1001-A in Patients With Advanced or Recurrent Solid TumorsPhase 1RecruitingAug 19, 20222027-07 (estimated)
NCT04072458A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesPhase 1Active, not recruitingNov 5, 20202025-04 (estimated)
NCT02923986Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSPhase 1/Phase 2WithdrawnSep 1, 2017May 27, 2020 (actual)
NCT01159028Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSPhase 1Completed2010-06Mar 30, 2017 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback